Merck KGaA (FRA:MRK) has been given a €90.00 ($111.11) price target by investment analysts at Commerzbank in a report released on Wednesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Commerzbank’s price objective would indicate a potential upside of 13.12% from the company’s current price.
Several other brokerages have also recently commented on MRK. Oddo Bhf set a €125.00 ($154.32) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Friday, November 10th. JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Friday, December 29th. DZ Bank reaffirmed a “buy” rating on shares of Merck KGaA in a research note on Monday, February 12th. UBS Group set a €120.00 ($148.15) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Friday, February 16th. Finally, Nord/LB reaffirmed a “neutral” rating on shares of Merck KGaA in a research note on Tuesday, January 2nd. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Merck KGaA has a consensus rating of “Buy” and a consensus target price of €105.76 ($130.57).
Merck KGaA (FRA:MRK) opened at €79.56 ($98.22) on Wednesday. The company has a market cap of $10,140.00 and a P/E ratio of 18.63. Merck KGaA has a 12 month low of €77.86 ($96.12) and a 12 month high of €115.00 ($141.98).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.